pcn poster

Posters

Pharmaceutical Pipeline of BI 1358894: Clinical Evidence for an Emerging Drug for the Treatment of Mental Health Conditions

Dysregulated emotional processing and overwhelming negative emotions are core symptoms of disorders such as posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) and ar...

Talal Al Habbab , PharmD;

10/26/2023

Pharmacogenomic Testing in Depression Care: Can Curriculum Based Online Education Improve Provider Knowledge, Competence, and Confidence?

Many clinicians are unaware of the evidence for pharmacogenomic (PGx) testing in depression care and are uncertain as to how to incorporate this modality into clinical decision making. Th...

Natalie Guevara , DVM, MPH;

10/26/2023

Opioid Antagonists: Clinical Utility, Pharmacology, and Safety and Tolerability

Pharmacology, clinical uses, and safety/tolerability of FDA-approved opioid antagonists are reviewed. Opioid antagonists treat opioid overdose, alcohol/opioid use disorder, and opioid-ind...

Mark Todtenkopf , PhD;

10/26/2023

Outcomes From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia

OASIS was an observational study that evaluated real-world outcomes of atypical long-acting injectable (aLAI) antipsychotics in patients with schizophrenia. Overall, CGI-S scores at basel...

Peter J. Weiden , MD, PhD;

10/26/2023

Patient Perspective on Idiopathic Hypersomnia: Impact on Quality of Life and Satisfaction With the Diagnostic Process and Management

This study assessed symptoms, impact, diagnosis, and management of idiopathic hypersomnia in US patients surveyed online. Most respondents reported they had been misdiagnosed before recei...

Marisa Whalen , PharmD;

10/26/2023

Patient Perspectives of Meaningful Change in Major Depressive Disorder

Findings from qualitative interviews with 19 US adult patients with major depressive disorder (MDD) highlighted the episodic and heterogeneous nature of MDD, as well as the importance of ...

Robin Tan , PhD;

10/26/2023

Patient Perspectives on Major Depressive Disorder Care to Inform Patient-Centered Approaches

To better understand patients’ experiences and perceptions of their major depressive disorder (MDD) care, we designed a 21-item survey to capture patient perceptions of their MDD symptoms...

Laura Simone , PhD;

10/26/2023

Patient Preferences and Nocturnal Experiences With Oxybate Therapy for Narcolepsy: RESTORE Study Interim Analysis

RESTORE (NCT04451668), an ongoing open-label/switch study evaluating the safety/tolerability of once-nightly sodium oxybate (ON-SXB), included 2 questionnaires administered to participant...

Asim Roy , MD;

10/26/2023

Multiple Factors Underlying Diagnostic Etiology of Psychosis: A Case Report.

27 year old male with history of HIV infection and substance abuse disorder arrived at the ER presenting aggressive behavior, errors of judgment and conduct, ego dystonic complex, auditor...

Patricio Mendoza Galvez , MD;

10/26/2023

No Signs of MDMA-Related Histopathological Changes to CNS in Rats and Dogs in A 28-Day Repeated Oral Dose Neurotoxicity Study

3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy is being investigated as a potential treatment option for patients with posttraumatic stress disorder (PTSD). Previous animal MDM...

Berra Yazar-Klosinski , PhD;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products